Brooklyn Investment Group Buys New Shares in Catalent, Inc. (NYSE:CTLT)

Brooklyn Investment Group acquired a new position in shares of Catalent, Inc. (NYSE:CTLT) in the third quarter, HoldingsChannel.com reports. The firm acquired 505 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds also recently modified their holdings of the company. Swedbank AB bought a new position in Catalent in the first quarter valued at approximately $1,659,000. DekaBank Deutsche Girozentrale grew its stake in shares of Catalent by 2.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock valued at $1,763,000 after buying an additional 732 shares in the last quarter. GAMMA Investing LLC increased its holdings in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the last quarter. DNB Asset Management AS raised its position in Catalent by 10.4% during the second quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock worth $1,721,000 after acquiring an additional 2,887 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent in the second quarter valued at $42,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CTLT. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Shares of NYSE CTLT opened at $61.11 on Friday. The business’s 50 day moving average is $59.90 and its 200-day moving average is $58.49. The firm has a market cap of $11.09 billion, a P/E ratio of -27.04, a price-to-earnings-growth ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.10) EPS. Equities research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 in the last quarter. 0.31% of the stock is currently owned by corporate insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.